AKT1 and gastric cancer: DARPP-32 has been shown to promote resistance of gastric cancer cells to EGFR inhibitors by promoting an interaction between EGFR and ERBB3, which drives PI3K/AKT signaling [49] to “bypass” EGFR TKI resistance.